• Trial to enrol final 12 patients at 1200mg dose
• Based on positive safety and clinical response data
• Next scheduled review late-January 2019
SYDNEY, December 11, 2018: Noxopharm (ASX:NOX) announces that the Company’s DARRT-1 clinical study has been approved to move to its final stage, with enrollment of the final 12 patients at a Veyonda dosage of 1200 mg.
The first stage, now fully enrolled, was a dose-finding study to establish the therapeutic dosage of Veyonda (400, 800 or 1200 mg).
For further information please download PDF attached:
Download this document
